A solution for treating contact lens is provided. The solution includes about 0.01-1.0 parts by weight (pbw) of a polymer having phosphorylcholine groups, about 0.01-1 pbw of an inorganic salt, and about 100 pbw of water. The polymer has a number-average molecular weight of about 4,000 to about 1,000,000 daltons and has a structure of formula (I):

##STR00001##

wherein, in formula (I), m is a positive integer, n is zero or a positive integer, and R is C.sub.2-C.sub.12 alkyl group or C.sub.2-C.sub.12 hydroxyalkyl group. When n is a positive integer, m/n is greater than 1.

A solution for treating a contact lens and a contact lens packaging system are provided. The solution includes about 0.01 to about 1.0 parts by weight (pbw) of a polymer having phosphorylcholine groups, about 0.005 to about 0.05 pbw of a hydrophilic molecule, about 0.01 to about 1.0 pbw of an inorganic salt, and about 100 pbw of water. A number-average molecular weight of the polymer is about 4,000 to about 1,000,000 daltons. The polymer has a structure of formula (I):

##STR00001##

wherein, in formula (I), m is a positive integer, n is zero or a positive integer, and R is C.sub.2-C.sub.12 alkyl group, or C.sub.2-C.sub.12 hydroxyalkyl group. When n is a positive integer, m/n is greater than 1. Moreover, a number-average molecular weight of the hydrophilic molecule is about 10,000 to about 5,000,000 daltons. The hydrophilic molecule is hyaluronic acid (HA) or hyaluronate salt.

A solution for treating a contact lens and a contact lens packaging system are provided. The solution includes about 0.01 to about 1.0 parts by weight (pbw) of a polymer having phosphorylcholine groups, about 0.005 to about 0.05 pbw of a hydrophilic molecule, about 0.01 to about 1.0 pbw of an inorganic salt, and about 100 pbw of water. A number-average molecular weight of the polymer is about 4,000 to about 1,000,000 daltons. The polymer has a structure of formula (I):

##STR00001##

wherein, in formula (I), m is a positive integer, n is zero or a positive integer, and R is C.sub.2-C.sub.12 alkyl group, or C.sub.2-C.sub.12 hydroxyalkyl group. When n is a positive integer, m/n is greater than 1. Moreover, a number-average molecular weight of the hydrophilic molecule is about 10,000 to about 5,000,000 daltons. The hydrophilic molecule is hyaluronic acid (HA) or hyaluronate salt.

Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, or reduce biofilms, or to inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.

The invention is related to a contact lens care solution comprising a buffer solution, a chelating agent, a surfactant and a wetting agent, wherein the wetting agent comprises 100 parts by weight of glycerol, 0.5 to 40 parts by weight of vinylacetamide-containing polymer and 5 to 40 parts by weight of alginic acid.

The invention is related to a contact lens care solution comprising a buffer solution, a chelating agent, a surfactant and a wetting agent, wherein the wetting agent comprises 100 parts by weight of glycerol, 0.5 to 40 parts by weight of vinylacetamide-containing polymer and 5 to 40 parts by weight of alginic acid.

The present invention addresses the problem of providing a novel application of meglumine or a salt thereof. The present invention is an antiseptic agent consisting of meglumine or a salt thereof, and a pharmaceutical composition comprising the antiseptic agent according to the present invention, and pertaining to: a pharmaceutical composition which does not comprise benzalkonium chloride and which is placed in a reusable container; a product that comprises the pharmaceutical composition comprising the antiseptic agent according to the present invention and a reusable container; and a method of improving the antiseptic effect of the pharmaceutical composition by comprising meglumine or a salt thereof in the pharmaceutical composition that has been placed in the reusable container.

Provided are compositions and methods related to improved mucins, methods of making the improved mucins, and cells and cell cultures that express glycosylated mucins. The compositions and methods provide improved cell cultures, and improved methods of producing co-expressed proteins that are distinct from the mucins.

The invention contemplates a copolymer which is a graft or block copolymer useful to change the ocular surface temperature and other characteristics of biological or contact lens surfaces. Methods for use of these formulations and coatings to increase the temperature of the skin, mucous membranes, eye or eyelids will help treat many conditions including blepharitis and non-healing ulcers. Methods to decrease evaporation, improve wettability and stabilize the tear film, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to improve contact lens tolerability, are provided.

The invention contemplates a copolymer which is a graft or block copolymer useful to change the ocular surface temperature and other characteristics of biological or contact lens surfaces. Methods for use of these formulations and coatings to increase the temperature of the skin, mucous membranes, eye or eyelids will help treat many conditions including blepharitis and non-healing ulcers. Methods to decrease evaporation, improve wettability and stabilize the tear film, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to improve contact lens tolerability, are provided.